SecurityCYTR / CytRx Corp. (232828509)
CEOKRIEGSMAN STEVEN A
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Institutional Owners13
Institutional Shares11,362,696 - 40.53%
Common Shares Outstanding28,037,501 shares (as of 2018-03-31)
Institutional Value$ 2,176,000 USD

Institutional Stock Ownership and Shareholders()

CYTR / CytRx Corp. Institutional Ownership

CytRx Corp. (NASDAQ:CYTR) has 13 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 11,362,696 shares. Largest shareholders include CVI Investments, Inc., BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, Northern Trust Corp, BlackRock Advisors LLC, Dimensional Fund Advisors Lp, Bank of New York Mellon Corp, MetLife Securities, Inc, and Commonwealth Equity Services, Inc.
CytRx Corp. (NASDAQ:CYTR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/cytr"><img src="https://images.fintel.io/us-cytr-so.png" alt="CYTR / CytRx Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 0 25,747 0 41
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 2,001 3,311 65.47 3 5 66.67
2018-04-26 13F-HR SIMPLEX TRADING, LLC 2,314 0 -100.00 3 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 52,267 41,510 -20.58 31 15 -51.61
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 1,808,962 1,840,097 1.72 1,064 685 -35.62
2017-02-07 13F-HR FIRST NEW YORK SECURITIES LLC /NY 29,699 0 -100.00 17,472 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 2,669,761 3,078,200 15.30 1,571 1,146 -27.05
2018-05-07 13F-HR Focused Wealth Management, Inc 0 685 0 1
2018-05-15 13F-HR Bank of New York Mellon Corp 0 25,690 0 40
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 16,759 16,759 0.00 11 7 -36.36
2017-02-10 SC 13G/A CVI Investments, Inc. 7,142,858 5,835,354 -18.31
2017-02-10 13F-HR BlackRock Investment Management, LLC 426,345 430,401 0.95 251 160 -36.25
2018-05-15 13F-HR BARCLAYS PLC 2 3 50.00 0 0
2017-01-13 13F-HR MetLife Securities, Inc 22,000 22,000 0.00 13 8 -38.46
2018-05-09 13F-HR NORTHERN TRUST CORP 43,062 42,939 -0.29 72 68 -5.56
CYTR: CytRx Corporation Stock Analysis and Research Report

2017-09-27 - Asif

CytRx Corporation is a biopharmaceutical company specializing in oncology. Its focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, it slead clinical candidate, has been tested in over 600 patients with various types of cancer. CytRx's lead product candidate is aldoxorubicin, a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of the tumor. Specifically, it is comprised of (6-maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its lead indication for aldoxorubicin is for patients with advanced soft tissue sarcomas (STS). It met with the FDA in March 2017 to discuss a regulatory pathway for a New Drug Application (NDA) for aldoxorubicin in STS. Aldoxorubicin has...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

More Red Flags For CNBC's Jon Najarian And Net Element Nete

2018-05-09 valuewalk
Its been a week since we publicly raised questions about why Jon Najarian of CNBC had not filed any Form 4s relating to shares he claimed to have purchased in Net Element Inc. (NETE). It remains unclear to us why he still has not filed these forms as required by the SEC, but the more time that passes the more we are inclined to believe that he never actually purchased the shares. (352-1)

Biotech Companies Continue to Shake Up Leadership with New Appointments

2018-05-08 biospace
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes. (449-3)

Your Daily Pharma Scoop: Conatus Data, Solid Biosciences' SGT-001, Ultragenyx's Crysvita Approved

2018-04-19 seekingalpha
Today we will discuss Conatus (NASDAQ:CNAT), which fell more than 4% in regular trading even as the company reported promising data with IDN-7314. (563-0)

BRIEF-Cytrx Presents Statistically Significant Breakthrough Data For Its Albumin Binding Ultra High Potency Ladr Drug Candidates

2018-04-18 reuters
* CYTRX PRESENTS STATISTICALLY SIGNIFICANT BREAKTHROUGH DATA FOR ITS ALBUMIN BINDING ULTRA HIGH POTENCY LADR DRUG CANDIDATES (288-1)

CUSIP: 232828509